Analysis of the antibody level against interferon beta before and afte
Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
Evaluation of the level of binding and neutralizing antibodies to interferin beta before and after increase of the dose from 22 to 44 micrograms/dose, with two years of follow-up after the change of dose
Immune response
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: Multiple sclerosis patients aged 18-65 years treated by Rebif 22 microgram/dose for more than 1 year. Exclusion: Insufficient patient compliance.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine whether increase from 22 microgram to 44 microgram per dose interferon beta-1a three times a week will reduce the level of binding and neutralizing antibodies to interferon beta by high dose tolerance or other mechanisms.
Loading reviews and guidelines…
Related trials
- An Observational Study to Learn About the Interferon-beta Exposure of
Running, not recruiting
Still running
- US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage a
Completed
No results found
- PROmyBETAappGame: a Study to Learn More About the Medication Usage & P
Completed
No results found
- EPID Multiple Sclerosis Pregnancy Study
Completed
No results found
- Comparison Study of PF530 and Betaferon in Healthy Subjects
Phase 1 · Completed
No results found
- Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterfer
Phase 1 · Completed
Paper found, not read
History
Started
Mar 2005